Hypochondroplasia (disorder)
BridgeBio’s Infigratinib Demonstrates Sustained Efficacy in Phase 2 Trial for Achondroplasia Treatment
BridgeBio, Infigratinib, Achondroplasia, Hypochondroplasia, Phase 2 Trial, Growth Disorder Treatment
Actionable Insights Powered by AI
BridgeBio, Infigratinib, Achondroplasia, Hypochondroplasia, Phase 2 Trial, Growth Disorder Treatment